Genetic analysis of thermolabile methylenetetrahydrofolate reductase as a risk factor for myocardial infarction

QJM: An International Journal of Medicine

Volumn 89, Issue 6, 1996, Pages 437-444

  Adams, M ^a   Smith, P D ^a   Martin, D ^a   Thompson, J R ^a   Lodwick, D ^a   Samani, N J ^a,b  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b GLENFIELD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ALANINE; HOMOCYSTEINE; METHIONINE; VALINE;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC RISK; GENOTYPE; HEART INFARCTION; HOMOZYGOSITY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLISM; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; THERMOSTABILITY;

EID: 0029975240     PISSN: 00335622     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/89.6.437     Document Type: Article

References (34)

1. Wilcken DEL, Wilcken B. The pathogenesis of coronary disease: a possible role for methionine metabolism. J Clin Invest 1976; 57:1079-82.
2. Murphy-Chutorian DR, Wexman MP, Grieco AJ, Heininger JA, Classman E, Gaull GE, Ng SK, Feit F, Wexman K, Fox A. Methionine intolerance: a possible risk factor for coronary artery disease. J Am Coll Cardiol 1985; 6:725-30.
3. Kang S-S, Wong PWK, Cook H, Norusis M, Messer JV. Protein-bound homocyst(e)ine: a possible risk factor for coronary artery disease. J Clin Invest 1986; 77:1482-6.
4. Israelsson B, Brattstrom LE, Hultberg BL. Homocysteine and myocardial infarction. Atherosclerosis 1988; 71:227-33.
5. Malinow MR, Sexton G, Averbuch M, Grossman M, Wilson D, Upson B. Homocyst(e)inemia in daily practice: levels in coronary artery disease. Coron Art Dis 1990; 1:215-20.
6. Genest JJ, McNamara JR, Salem DN, Wilson PWF, Schaefer EJ, Malinow MR. Plasma homocyst(e)ine levels in men with premature coronary artery disease. J Am Coll Cardiol 1990; 16:1114-19.
7. Williams RR, Malinow MR, Hunt Sc, Upson B, Wu LL, Hopkin PN, Stults BN, Kuida H. Hyperhomocyst(e)inemia in Utah siblings with early coronary disease. Coron Art Dis 1990; 1:681-5.
8. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324:1149-55.
9. Stampfer MJ, Malinow MR, Wilett WC, Newcomer LM, Upson B, Ullmann D, Tishler PV, Hennekens CH. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992; 268:877-81.
10. Brattstrom LE, Israelsson B, Jeppsson J-O, Hultberg BL. Folic acid - an innocuous means to reduce plasma homocysteine. Scand J Clin Lab Invest 1988; 48:215-21.
11. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993; 270:2683-98.
12. Mudd SH, Levy HL, Skovby F. Disorders of transulfuration. In: Scriver C, Beaudet AL, Sly WS, Valle D, eds. The metabolic basis of inherited disease, 6th edn, Vol. 1. New York, McCraw-Hill, 1989;693-734.
13. Carey MC, Donovan DE, Fitzgerald O, McAuley FD. Homocystinuria: a clinical and pathological study of 9 subjects in six families. Am J Med 1968; 45:7-25.
14. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969; 56:111-28.
15. Ueland PM, Refsum H. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease and drug therapy. J Lab Clin Med 1989; 114:473-501.
16. Daly L, Robinson K, Tan KS, Graham I. Hyperhomocysteinemia: a metabolic risk factor for coronary heart disease determined by both genetic and environmental influences? Q J Med 1993; 86:685-9.
17. Kang S-S, Zhou J, Wong PWK, Kowalisyn J, Strokosch G. Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet 1988; 43:414-21.
18. Kang S-S, Wong PWK, Susmano A, Sora J, Norusis M, Ruggie N. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet 1991; 48:536-45.
19. Kang S-S, Passen EL, Ruggie N, Wong PWK, Sora H. Thermolabile defect of methylenetetrahydrofolate reductase in coronary artery disease. Circulation 1993; 88(part 1):1463-9.
20. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJH, den Heijer M, Kluijtmans LAJ, van den Heuvel LP, Rozen R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10:111-13.
21. WHO (Report of the joint International Society and Federation of Cardiology/World Health Organisation Task Force on standardization of clinical nomenclature). Nomenclature and criteria for diagnosis of ischaemic heart disease. Circulation 1979; 59:607-9.
22. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: A laboratory manual. Cold Spring Harbor, Laboratory Press, 1989.
23. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969; 56:111-28.
24. Brattstrom LE, Hardebo JE, Hultberg BL. Moderate homocysteinemia: a possible risk factor for arteriosclerotic cerebrovascular disease. Stroke 1984; 15:1012-16.
25. Malinow MR, Kang S-S, Taylor LM, Wong PWK, Coull B, Inan T, Murkerjee D, Sexton G, Upson B. Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease. Circulation 1989; 79:1180-8.
26. Boers GHJ, Smals AGH, Trijbels FJM, Fowler B, Bakkeren JAJM, Schoonderwaldt HC, Kleijer WJ, Kloppenborg PWC. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 1985; 313:709-15.
27. Stampfer MJ, Malinow MR. Can lowering homocysteine levels reduce cardiovascular risk? N Engl J Med 1995; 332:328-9.
28. Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D, Loscalzo J. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993; 91:308-18.
29. Tsai J-C, Perrella MA, Yoshizumi M, Hsieh CM, Haber E, Schlegel R, Lee ME. Promotion of vascular smooth muscle cell by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA 1994; 91:6369-73.
30. Heinecke JW, Rosen H, Suzuki LA, Chait A. The role of sulfur-containing amino acids in superoxide production and modification of low density lipoprotein by arterial smooth muscle cells. J Biol Chem 1987; 262:10098-103.
31. Rodgers GM, Conn MT. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood 1990; 73:895-901.
32. Tiret L, Kee F, Poirier O, Ricard S, Marques-Vidal P, Evans A, Arveiler D, Luc C, Kee F, Ducimetiere P, Soubrier F, Cambien F. Deletion polymorphism in the angiotensin-converting enzyme gene associated with parental history of myocardial infarction. Lancet 1993; 341:991-2.
33. Morris BJ, Zee RYL, Schrader AP. Different frequencies of angiotensin-converting enzyme genotypes in older hypertensive individuals. J Clin Invest 1994; 94:1085-9.
34. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, Selhub J, Rozen R. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996; 93:7-9.